Television investment personality Jim Cramer made recommendations on these stocks on the August 2 episode of “Mad Money.” We review how these stocks performed over the weeks since to see if Cramer was on the money.

Alkermes Plc (ALKS) – Cramer issued a “Buy” recommendation on this small-cap biotechnology company that develops drugs for the treatment of addiction, mental disorders, diabetes and other conditions as well as intravenous and oral delivery products. It was founded in 1987.

It is currently trading around $15.60 a share, which is in the middle of its 52-week range of $9.85 to $20. The day after Cramer’s recommendation, ALKS opened at $16.53, up $0.10 from the previous day, and closed at $16. In the weeks that followed Cramer’s recommendation, ALKS’s closing price fluctuated between a low of $13.91 on Aug. 10 and a high of $17.37 on Aug. 30.

It is showing a loss per share of $0.48. Its five-year price/earnings to growth ratio is 0.25. Price to book value is higher than we’d like to see at 3.71. It is showing a negative return on equity of 11.38 percent. Its market capitalization is $1.5 billion.

Its competitor Amylin Pharmaceuticals Inc. (AMLN) shows a loss per share of $0.96. Its price/earnings to growth ratio is -0.31. Its price to book value at 4.42 is even higher, and it also shows a negative return on equity of 39.18 percent. It is trading near $9.80 and has fluctuated between $9.41 and $22 over the past year. To continue reading, click here.